Want to see ALPS full AI Analyst Report?
ALPS Group (ALPS) AI Stock Analysis
ALPS Group
(NASDAQ:ALPS)
The score is primarily weighed down by weak financial performance (persistent losses, ongoing cash burn, and negative equity), which increases funding and dilution risk. Technicals are mixed-to-weak with the stock below key longer-term moving averages, while valuation is difficult to support due to negative earnings and no dividend yield.
ALPS Group (ALPS) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $54.08M
- Dividend Yield
- ―
- Average Volume (3M)
- 55.73K
- Price to Earnings (P/E)
- -0.7
- Beta (1Y)
- 0.30
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 93
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
ALPS Group Business Overview & Revenue Model
Company Description
Alps Group Inc. operates as a comprehensive biotechnology firm, delivering a wide array of services ranging from groundbreaking research and development to direct medical care and health optimization initiatives, with a primary focus on cutting-edge...
How the Company Makes Money
ALPS makes money primarily by selling electronic components and integrated modules to business customers (OEMs and tier suppliers) that incorporate these parts into finished products such as vehicles, consumer electronics, and industrial devices. Key...
ALPS Group Financial Statement Overview
Summary
Despite strong recent revenue rebound, fundamentals remain stressed: TTM net margin is deeply negative (~-41%) with ongoing operating losses, operating cash flow and free cash flow are negative (continued cash burn), and stockholders’ equity has turned negative (higher financing/flexibility risk). Free cash flow has improved versus 2025, but the company is still not self-funding.
Income Statement
22NegativeBalance Sheet
18Very NegativeCash Flow
20Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 4.86M | 3.37M | 2.40M | 3.59M | 0 |
| Gross Profit | 0 | 1.56M | 1.30M | 598.93K | 1.98M | 0 |
| EBITDA | -1.51M | -901.36K | -1.35M | -1.45M | 363.17K | -135.65K |
| Net Income | -2.73M | -2.01M | -2.51M | -2.30M | -729.16K | -119.63K |
Balance Sheet | ||||||
| Total Assets | 1.74M | 6.97M | 7.13M | 6.70M | 119.22M | 117.96M |
| Cash, Cash Equivalents and Short-Term Investments | 357.73K | 607.47K | 318.93K | 460.47K | 81.76K | 812.23K |
| Total Debt | 5.91M | 559.27K | 6.93M | 507.57K | 0 | 0 |
| Total Liabilities | 12.97M | 10.20M | 8.25M | 5.25M | 4.84M | 4.37M |
| Stockholders Equity | -11.23M | -2.92M | -888.56K | 1.57M | 113.81M | 113.59M |
Cash Flow | ||||||
| Free Cash Flow | -962.42K | -2.63M | -1.69M | -1.59M | -388.04K | -324.87K |
| Operating Cash Flow | -962.42K | -2.58M | -1.61M | -1.37M | -113.57K | -324.87K |
| Investing Cash Flow | 28.77M | 26.60M | -100.06K | -1.71M | -288.29K | -116.72M |
| Financing Cash Flow | -27.51M | -24.39M | 1.87M | 3.28M | 212.92K | 117.86M |
ALPS Group Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALPS, the sentiment is Negative. The current price of 0.32 is below the 20-day moving average (MA) of 0.34, below the 50-day MA of 0.37, and below the 200-day MA of 0.68, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 27.46 is Positive, neither overbought nor oversold. The STOCH value of -5.73 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ALPS.
ALPS Group Risk Analysis
ALPS Group disclosed 77 risk factors in its most recent earnings report. ALPS Group reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksALPS Group Peers Comparison
Overall Rating
GANX48Neutral
ATRA46Neutral
MAIA44Neutral- ALPS41Neutral
ANVS40Underperform
KLRS40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| GANX | 48Neutral | $49.32M | -2.26 | -161.58% | ― | ― | 23.02% |
| ATRA | 46Neutral | $80.40M | -6.79 | 44.67% | ― | -96.72% | -253.97% |
| MAIA | 44Neutral | $67.92M | -1.74 | -211.15% | ― | ― | -7.28% |
| ALPS | 41Neutral | $54.08M | -0.68 | 20.73% | ― | ― | ― |
| ANVS | 40Underperform | $48.23M | -0.63 | -685.96% | ― | ― | 11.96% |
| KLRS | 40Underperform | $44.34M | -1.00 | -71.71% | ― | ― | 73.44% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ALPS | Alps Group Inc | 0.33 | -1.09 | -77.11% | |
| ATRA | Atara Biotherapeutics Inc | 8.01 | -5.84 | -42.17% | |
| ANVS | Annovis Bio Inc | 1.13 | -0.89 | -44.06% | |
| KLRS | Kalaris Therapeutics, Inc. | 2.03 | -2.96 | -59.32% | |
| GANX | Gain Therapeutics, Inc. | 1.13 | -0.71 | -38.59% | |
| MAIA | MAIA Biotechnology, Inc. | 1.10 | -0.06 | -5.17% |
ALPS Group Corporate Events
Alps Group Wins Shareholder Backing for Share Consolidation and Capital Increase
On October 30, 2026, Alps Group Inc held an Extraordinary General Meeting at which shareholders overwhelmingly approved a one-for-five consolidation of both ordinary and preferred shares and a related restructuring of authorized capital. The move wil...
Alps Group Reschedules Extraordinary General Meeting to October 30, 2026
Alps Group Inc has issued a Form 6-K dated October 15, 2026, to notify investors of a supplement to its proxy materials for an upcoming Extraordinary General Meeting of shareholders. The meeting, originally set for October 21, 2026, has been postpone...
Alps Group Calls October 21 EGM to Approve Share Consolidation and Capital Increase
Alps Group Inc has called a virtual extraordinary general meeting of shareholders for October 21, 2026, as disclosed in a Form 6-K filed on October 8, 2026, to vote on a series of capital structure changes. Registered shareholders as of the October 5...
Alps Group Posts 44% Revenue Growth in FY2026 as Nasdaq‑Listed Biotech Sharpens Precision Medicine Focus
Alps Group Inc, an integrated biotechnology platform based in Kuala Lumpur, generates revenue from cellular therapies, medical testing, aesthetics services and healthcare products to support its pipeline in precision medicine. Operating across cell m...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 17, 2026